RADIATION MODULATES THE PEPTIDE REPERTOIRE, ENHANCING MHC CLASS I EXPRESSION AND IMPROVING ANTI-TUMOR IMMUNO-THERAPY

被引：0

作者：

Neefjes, J. ^{[1
]}

Qiao, X. ^{[1
]}

Pang, B. ^{[1
]}

机构：

[1] NKI AVL, Tumor Biol, Amsterdam, Netherlands

来源：

RADIOTHERAPY AND ONCOLOGY | 2008年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

509

引用

页码：S168 / S168

页数：1

共 50 条

[31] Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients
Palermo, Belinda
Franzese, Ornella
Di Donna, Cosmo
Panetta, Mariangela
Quintarelli, Concetta
Sperduti, Isabella
Gualtieri, Novella
Foddai, Maria Laura
Proietti, Enrico
Ferraresi, Virginia
Ciliberto, Gennaro
Nistico, Paola
ONCOIMMUNOLOGY, 2018, 7 (12):
[32] TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
Ota, Yosuke
Inagaki, Ryosaku
Nagai, Yasuhiro
Hirose, Yuko
Murata, Masashi
Yamamoto, Setsuko
BMC IMMUNOLOGY, 2024, 25 (01)
[33] MHC class II and CD1d expressing conventional dendritic cells with immunoglobulin therapy drives anti-tumor abscopal effect by recruiting Natural Killer T cells to the tumor microenvironment
Garg, Saurabh K.
Snyder, Colin
Ramamoorthi, Ganesan
Evans, Elizabeth E.
Aldrich, Amy L.
Gautam, Namrata
Wiener, Doris
Lee, Marie C.
Han, Hyo S.
Gary, Koski K.
Czerniecki, Brian J.
CANCER RESEARCH, 2024, 84 (03)
[34] Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity
Duong, Ellen
Fessenden, Tim B.
Lutz, Emi
Dinter, Teresa
Yim, Leon
Blatt, Sarah
Bhutkar, Arjun
Wittrup, Karl Dane
Spranger, Stefani
IMMUNITY, 2022, 55 (02) : 308 - +
[35] Suppression of Major Histocompatibility Complex (MHC) Class I and II Mediates Resistance to Anti-PD-1 in Lung Adenocarcinoma Tumors That Can Be Overcome by Radiation Therapy
Wang, X.
Schoenhals, J. E.
Valdecanas, D. R.
Li, A.
Ye, H.
Zhang, F.
Tang, M.
Tang, C.
Liu, C. G.
Liu, X.
Komaki, R. U.
Gomez, D. R.
Chang, J. Y.
Cortez, M. A.
Welsh, J. W.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S89 - S89
[36] Natural Splice Variant of MHC Class I Cytoplasmic Tail Enhances Dendritic Cell-Induced CD8+ T-Cell Responses and Boosts Anti-Tumor Immunity
Rodriguez-Cruz, Tania G.
Liu, Shujuan
Khalili, Jahan S.
Whittington, Mayra
Zhang, Minying
Overwijk, Willem
Lizee, Gregory
PLOS ONE, 2011, 6 (08):
[37] Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells
Maiti, Aparna
Qi, Qianya
Peng, Xuan
Yan, Li
Takabe, Kazuaki
Hait, Nitai C.
INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 55 (01) : 116 - 130
[38] Selective class I HDAC inhibitor SNDX-275 enhances anti-tumor survivin vaccine therapy by suppressing regulatory T cells in a model of prostate cancer
Shen, Li
Ciesielski, Michael
Ellis, Leigh
Fenstermaker, Robert
Pili, Roberto
CANCER RESEARCH, 2011, 71
[39] MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR
Soto, Carolina M.
Stone, Jennifer D.
Chervin, Adam S.
Engels, Boris
Schreiber, Hans
Roy, Edward J.
Kranz, David M.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (02) : 359 - 369
[40] MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR
Carolina M. Soto
Jennifer D. Stone
Adam S. Chervin
Boris Engels
Hans Schreiber
Edward J. Roy
David M. Kranz
Cancer Immunology, Immunotherapy, 2013, 62 : 359 - 369

← 1 2 3 4 5 →